Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sargramostim - Bayer HealthCare Pharmaceuticals/Partner Therapeutics

Drug Profile

Sargramostim - Bayer HealthCare Pharmaceuticals/Partner Therapeutics

Alternative Names: BI 61012; GZ 402664; Leukine; Leukine Liquid; NPC-26; Prokine; Recombinant human GM‑CSF; rhuGM-CSF; Sargramostim - Bayer HealthCare Pharmaceuticals; sargramostim-biosimilar

Latest Information Update: 22 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Bayer HealthCare Pharmaceuticals Inc.; Cincinnati Children's Hospital Medical Center; Dana-Farber Cancer Institute; National Cancer Institute (USA); National Institute on Aging; Niigata University; Nobelpharma; Partner Therapeutics; Sanofi; University of California at Irvine; University of California at San Francisco; University of Colorado at Denver; University of Nebraska Medical Center; University of Texas M. D. Anderson Cancer Center; Virginia Commonwealth University
  • Class Adjuvants; Anti-infectives; Antidementias; Antineoplastics; Antiparkinsonians; Chemoprotectants; Granulocyte-macrophage colony-stimulating factors; Radioprotectives
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants; Macrophage stimulants; Neutrophil stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Pulmonary alveolar proteinosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Sepsis

Highest Development Phases

  • Marketed Acute radiation syndrome; Bone marrow disorders; Neutropenia; Pneumococcal infections; Stem cell mobilisation
  • Preregistration Pulmonary alveolar proteinosis
  • Phase III COVID 2019 infections
  • Phase II Acute hypoxia; Alzheimer's disease; Chronic lymphocytic leukaemia; Haematological malignancies; Malignant melanoma; Mycobacterial infections; Prostate cancer; Skin cancer
  • Phase I Unspecified
  • Preclinical Down syndrome; Sepsis
  • No development reported Ovarian cancer; Parkinson's disease
  • Discontinued Crohn's disease; Follicular lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 20 Dec 2023 Efficacy and adverse events data from a phase II SCOPE trial in COVID-2019 infections released by Partner Therapeutics
  • 30 Nov 2023 Clinical trials in Pulmonary alveolar proteinosis (SC) prior to November 2023
  • 30 Nov 2023 Efficacy and adverse events data from a clinical trial in Pulmonary alveolar proteinosis released by Partner Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top